Japan Market Report for Female Urinary Incontinence Slings 2017 - MedCore is a new market research publication announced by Reportstack.
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The female urinary incontinence sling market in Japan differs from the global market because biological slings are not commercially available. Synthetic slings comprise almost an exclusive monopoly for the type of products offered, with autologous tissue repair accounting for a nominal percentage of total procedures. Additionally, synthetic mesh is not sold as individual kits in Japan. Hospitals purchase rolls of synthetic mesh and the physician cuts the mesh to size. The Japanese market is further differentiated by the lack of competition. Boston Scientific and Ethicon are the only two competitors offering products on the market.
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The female urinary incontinence sling market in Japan differs from the global market because biological slings are not commercially available. Synthetic slings comprise almost an exclusive monopoly for the type of products offered, with autologous tissue repair accounting for a nominal percentage of total procedures. Additionally, synthetic mesh is not sold as individual kits in Japan. Hospitals purchase rolls of synthetic mesh and the physician cuts the mesh to size. The Japanese market is further differentiated by the lack of competition. Boston Scientific and Ethicon are the only two competitors offering products on the market.
Complete report available @ Japan Market Report for Female Urinary Incontinence Slings 2017 - MedCore
In 2016, the female urinary incontinence sling market began to recover slightly. The volatility in the market is attributed towards ongoing scrutiny by healthcare regulatory agencies such as the FDA in the United States and adverse reactions documented by the Japan Society of Obstetrics and Gynecology (JSOG). The controversy surrounding urinary incontinence slings predominantly concerns synthetic slings. Due to the negative side effects publicized about slings, however, procedures using both synthetic and biological slings have decreased globally. The adverse side-effects have resulted in patients and, to a lesser degree, physicians, becoming more cautious about sling procedures. While the repercussions of this controversy will still extend throughout the forecast period, as a result surgeons are giving greater attention to stronger patient consent protocols including full disclaimers of the risks involved.
The negative publicity regarding slings has had the greatest impact in countries without public healthcare. In Japan, there has been a faster response to treat patients with adverse effects with no additional costs for the patient. This has led to fewer lawsuits and complaints regarding the procedure helping to keep the market stable.
Despite the contraction of the urinary incontinence sling market, the number of procedures is still substantial. The number of patients suffering from female urinary incontinence is increasing. The number of patients is also expected to continue increasing over the forecast period, as urinary incontinence affects older demographics.
It is worth noting that biological mesh is not available for female urinary incontinence slings due to the regulatory framework for medical devices in Japan. However, even globally this segment comprises a very small portion of the overall market because many believe that collagen based mesh is not as applicable in this indication compared to other areas such as breast reconstruction or hernia repair. There is also a lack of clinical data supporting the use of biologic mesh over synthetic mesh for the treatment of stress incontinence.
It is worth noting that biological mesh is not available for female urinary incontinence slings due to the regulatory framework for medical devices in Japan. However, even globally this segment comprises a very small portion of the overall market because many believe that collagen based mesh is not as applicable in this indication compared to other areas such as breast reconstruction or hernia repair. There is also a lack of clinical data supporting the use of biologic mesh over synthetic mesh for the treatment of stress incontinence.
Scope
2013-2023
2013-2023
Companies Mentioned
Kitazato Cook Medical Olympus Cooper Surgical Boston Scientific Vitrolife Irvine Scientific Naka Medical Johnson & Johnson Karl Storz Vitromed Rocket Medical Medi-Con International Carl Zeiss Sankyo Medical Pentax Life Global (IVF Online) Astec Bio The Pipette Company Esco Global Stryker Richard Wolf Merit Medical Systems BTG Leica Medtronic Others include: Nidacon Medical, Reproline Medical, ThermoFisher, AngioDynamics, Welch Allyn, local competitors, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
No comments:
Post a Comment